Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/35766
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Galsulfase
Author: Hopwood, J.
Bate, G.
Kirkpatrick, P.
Citation: Nature Reviews Drug Discovery, 2006; 5(2):101-102
Publisher: Nature Publishing Group
Issue Date: 2006
ISSN: 1474-1776
1474-1784
Statement of
Responsibility: 
John J. Hopwood; Guy Bate; Peter Kirkpatrick
Abstract: In May 2005, galsulfase (Naglazyme; BioMarin), a recombinant form of human N-acetylgalactosamine 4-sulfatase, was approved by the US FDA for the treatment of patients with mucopolysaccharidosis type VI, a rare lysosomal storage disorder caused by a deficiency of N–acetylgalactosamine 4-sulfatase. It is the first approved product for the treatment of mucopolysaccharidosis type VI, and has been granted orphan drug status.
Keywords: CHO Cells
Animals
Humans
Mucopolysaccharidosis VI
N-Acetylgalactosamine-4-Sulfatase
Recombinant Proteins
Female
Cricetinae
DOI: 10.1038/nrd1962
Appears in Collections:Aurora harvest
Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.